Table 5.
Results of model extensions for number of screens (undiscounted)
| No of screens | No screening | Screening for type 2 diabetes only | Screening for type 2 diabetes and impaired glucose tolerance | |
|---|---|---|---|---|
| Lifestyle interventions | Pharmacological interventions | |||
| QALY | ||||
| 1 | 28.06 (23.49 to 32.01) | 28.12 (23.58 to 32.08) | 28.26 (23.74 to 32.23) | 28.22 (23.69 to 32.18) |
| 2 | 28.06 (23.49 to 32.01) | 28.13 (23.74 to 32.06) | 28.56 (24.74 to 32.30) | 28.44 (24.45 to 32.24) |
| 3 | 28.06 (23.49 to 32.01) | 28.15 (23.86 to 32.16) | 28.80 (25.04 to 32.32) | 28.62 (24.70 to 32.26) |
| Total cost (£) | ||||
| 1 | 17 290 (5746 to 39 580) | 18 040 (7083 to 39 970) | 17 910 (7124 to 39 740) | 17 900 (7061 to 39 710) |
| 2 | 17 290 (5746 to 39 580) | 18 850 (7491 to 40 980) | 19 300 (7570 to 41 160) | 19 150 (7468 to 41 150) |
| 3 | 17 290 (5746 to 39 580) | 19 670 (7735 to 42 110) | 20 220 (7740 to 42 210) | 19 860 (7621 to 42 210) |
| Cost per QALY gained (£) | ||||
| 1 | — | 8681 | 2863 | 3429 |
| 2 | — | 9544 | 2777 | 3317 |
| 3 | — | 10 360 | 2966 | 3517 |
| Probability of being cost effective at willingness to pay threshold of £20 000/£30 000 per QALY (%) | ||||
| 1 | — | 68/76 | 99/100 | 95/97 |
| 2 | — | 57/66 | 99/100 | 96/98 |
| 3 | — | 54/64 | 99/100 | 97/99 |